Brivudine

This classification denotes a pyrimidine antagonist and antiviral agent with the molecular formula C11H13BrN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2M3055079H, chemically known as uridine, 5-(2-bromovinyl)-2-deoxy-, (e)- but generally known as brivudine, which bears US NIH Compound Identifier 446727. European Medicines Agency schedules Brivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05893MIG. The term BRIVUDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules brivudine in its Anatomical Therapeutic Chemical (ATC) Classification. BRIVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brivudine under HS 29349990 and SITC 51579. As of Q4 2014, BRIVUDINE remains the US FDA Preferred Term for this commodity. Brivudine bears US NLM identifiers UMLS ID C0163272 and NCI Concept Code C67088. SMILES: C1C(C(OC1N2C=C(C(=O)NC2=O)C=CBr)CO)O.